Why Stockouts Persist Across Multi-Site Networks (and How to Fix Them)

In a single plant, a stockout usually has an obvious owner. Across a network of sites, it rarely does. Having worked on stockouts across a 14-site medical device network, I’ve seen the same pattern: every individual stockout gets expedited, and the system that produces them never changes.

Why they keep coming back

  • Many causes, no common view. Supplier delays, quality holds, capacity, planning parameters and transfers all show up as the same symptom.
  • Local optimization. Each site manages its own metrics; the network-level cost is nobody’s KPI.
  • Stale planning settings. Safety stock and lead-time parameters drift from reality.
  • Expediting as the system. Heroics fix today’s shortage and hide tomorrow’s.

A practical fix

  1. One list. Track every stockout across the network in one place with a consistent definition.
  2. Classify by root cause, not by site.
  3. Rank by dollars. Lost or delayed revenue tells you where effort pays back first.
  4. Govern across sites. A regular cross-site review gives each cause an owner and a date.
  5. Fix the system. Update parameters, supplier agreements and hold processes so the cause does not return.

The goal is not zero expediting; it is fewer surprises, measured in dollars. See the 14-site stockout case study, learn about my operational excellence work, or get in touch.

Medical Device Product Transfer Checklist: 10 Things to Settle Before You Move

Product transfers between sites or to a contract manufacturer look straightforward on a plan and rarely are in practice. Most delays trace back to decisions that were never made explicitly at the start. Here are ten to settle before anything moves.

  1. Exact scope. Which SKUs, configurations, components and processes are moving, and which are not.
  2. Regulatory impact. Whether the change requires a submission or notification in each market, and how long that takes.
  3. Documentation readiness. Whether the device master record, specifications and work instructions are complete and current enough to transfer.
  4. Validation strategy. What needs installation, operational and performance qualification at the receiving site, and what can be leveraged.
  5. Supplier and component changes. Whether suppliers change too, and what qualification that triggers.
  6. Equipment and tooling. Move, duplicate or buy, with lead times confirmed.
  7. Bridge inventory. How much stock to build ahead so customers never see the transition.
  8. Labeling changes. Manufacturer address, UDI and other labeling impacts.
  9. People and knowledge. Training, and how tacit know-how at the sending site will be captured.
  10. Acceptance criteria. The yield, quality and capacity levels that define “transferred,” and who signs off.

Why this matters

Each of these is cheap to decide at planning and expensive to discover at validation. A transfer plan that answers all ten in writing, with owners, is usually a transfer that lands on time.

I lead product transfers and NPI programs for medical device manufacturers. If a transfer is on your roadmap, let’s talk.

What to Do in the First 30 Days After an FDA 483

An FDA Form 483 lists the investigator’s observations at the end of an inspection. It is not a final agency decision, but how a company responds strongly shapes what happens next. In my experience leading remediation programs in medical device manufacturing, the first 30 days decide whether the response is credible and whether the business keeps shipping.

Days 1–3: triage and ownership

  • Name one accountable executive and one program lead. Remediation without a single owner drifts.
  • Assign each observation a technical owner and a first assessment date.
  • Quantify business exposure immediately: which SKUs, how much revenue and which customers are affected if product is held.
  • Decide what, if anything, must be contained now rather than after the response.

Days 4–15: write a response you can keep

FDA generally considers responses received within 15 business days when deciding whether further action is needed. A strong response addresses each observation with root cause, correction, corrective action, systemic review beyond the specific example, and dates.

The most common mistake is overpromising. Dates written under pressure become commitments the agency will check. Build the response from a real plan, not the other way around.

Days 15–30: turn the response into a program

  • Structure pathways. Separate fast recovery of held product from the durable fix and from longer-term resilience, so the business isn’t waiting on the slowest path.
  • Set the rhythm. Daily management for the working team, a weekly steering committee for decisions, and concise reporting to the CEO.
  • Line up outside capacity early. External labs, contract sterilizers and consultants have lead times of their own.
  • Report in revenue as well as milestones. Leaders fund what they can see.
  • Plan follow-up updates to the agency so progress is visible.

What good looks like at day 30

A submitted response you are confident you can deliver, a funded plan with owners and dates for every observation, a clear view of revenue at risk and the recovery path for each SKU, and a governance rhythm that is already running.

If you are facing a 483 or a product hold, I lead remediation programs for medical device manufacturers. See how a three-pathway sterilization remediation recovered $15M+ in revenue, or get in touch.